Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies.
Pflug N, Chakupurakal G, Fink AM, Robrecht S, Herling M, Cramer P, Holtick U, Theurich S, Schetelig J, Fischer K, Ritgen M, Scheid C, Eichhorst B, Dreger P, Hallek M, von Bergwelt-Baildon M. Pflug N, et al. Among authors: holtick u. Hemasphere. 2021 Nov 12;5(12):e664. doi: 10.1097/HS9.0000000000000664. eCollection 2021 Dec. Hemasphere. 2021. PMID: 34881358 Free PMC article. No abstract available.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Schuster SJ, et al. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501490 Clinical Trial.
Toll-like receptor 9 agonists as cancer therapeutics.
Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Holtick U, et al. Expert Opin Investig Drugs. 2011 Mar;20(3):361-72. doi: 10.1517/13543784.2011.553187. Epub 2011 Jan 22. Expert Opin Investig Drugs. 2011. PMID: 21254877 Review.
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia.
Chemnitz JM, von Lilienfeld-Toal M, Holtick U, Theurich S, Shimabukuro-Vornhagen A, Krause A, Brossart P, Hallek M, Scheid C. Chemnitz JM, et al. Among authors: holtick u. Ann Hematol. 2012 Jan;91(1):47-55. doi: 10.1007/s00277-011-1253-9. Epub 2011 May 17. Ann Hematol. 2012. PMID: 21584670
Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer.
Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, Weihrauch MR, von Bergwelt-Baildon M, Hacker UT. Goede V, et al. Among authors: holtick u. Cancer Invest. 2012 Mar;30(3):225-30. doi: 10.3109/07357907.2011.636114. Epub 2011 Dec 15. Cancer Invest. 2012. PMID: 22171993
Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M. Theurich S, et al. Among authors: holtick u. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Cochrane Database Syst Rev. 2012. PMID: 22972135 Updated. Review.
106 results